The NET-PD LS-1 dataset has allowed for multiple associations between different factors of life for those affected by Parkinson's disease to be examined. The objective of this study was to evaluate any possible associations between levodopa-equivalent daily dosage and frequency of adverse events in the LS-1 subjects. Multiple linear regression was used to evaluate the LEDD and adverse events data while adjusting for covariates and possible confounders. Missing data were also imputed in order to facilitate a more thorough analysis. A 100 mg change in LEDD was found to be associated with a 12% increase in the rate of adverse events per year. The imputations also uncovered associations between the likelihood of certain body systems experiencing adverse events and the number of adverse events per year. This raises possible issues with current dopaminergic therapy regimens, as they may possibly be linked to adverse health outcomes.